Safety and efficacy of tumor necrosis factor α blockade in systemic lupus erythematosus: An open‐label study

Abstract

Infliximab did not lead to adverse events related to an increase in SLE activity, although autoantibodies to double-stranded DNA and cardiolipin increased, as expected. This finding, coupled with the clinical improvement in the inflammatory manifestations of the disease, indicates that further study in larger controlled trials is warranted.